Ligand Pharmaceuticals Incorporated (LGND) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Ligand Pharmaceuticals Incorporated (LGND) is Moderate Outperform.

The composite score behind that read is +0.33, weighing +0.44 of bullish evidence against -0.10 bearish.

Ligand Pharmaceuticals Incorporated last closed at $301.81, +2.31% on the session.

Against the IVW growth benchmark the position is +1.51% over the forecast window.

The read is built from 15 underlying insights — 12 bullish and 3 bearish.

Agreement across those insights is 80%.

9 graded predictions for LGND so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks Ligand Pharmaceuticals Incorporated in the 27th percentile on valuation and the 80th percentile on return on equity, where 100 is best.

Ligand Pharmaceuticals Incorporated is classified under Health Care / Pharmaceuticals, with a market capitalisation of $5.88B.

StockMap tracks Ligand Pharmaceuticals Incorporated as the 23rd largest of the 151 companies it covers in the Pharmaceuticals industry, part of the Health Care sector.

Across that group the current two-week reads are 90 Neutral, 46 Moderate Underperform and 15 Moderate Outperform.

On that composite Ligand Pharmaceuticals Incorporated ranks 3rd of 151 in the group, against a group median of -0.08.